Dyno Therapeutics launches two new AAV Capsids, AI platform for rare disease therapeutic development: Watertown, Massachusetts Saturday, May 16, 2026, 13:00 Hrs [IST] Dyno Therape ...

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...

PackGene Biotech, Inc. announced today six presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting in Boston, May 11–15, highlighting the company's continued ...

Trial data demonstrated that the therapy was well tolerated and achieved reductions in HBV DNA and RNA across both HBeAg-positive and HBeAg-negative patients. The Food and Drug Administration (FDA) ...

Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...

The alternative text for this image may have been generated using AI. We first analyzed the six AAV2 capsid mutants (I-261, I-381, I-447, I-534, I-573 and I-587) for their ability to package the viral ...

Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced the launch of two new ...

Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating ...

Viral vectors are key delivery tools for advanced therapies, enabling gene transfer to treat inherited disorders, cancer and other serious diseases. Despite rapid clinical progress, manufacturing ...

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress.Six ...